Literature DB >> 11581431

Human cytomegalovirus protein US2 interferes with the expression of human HFE, a nonclassical class I major histocompatibility complex molecule that regulates iron homeostasis.

S V Ben-Arieh1, B Zimerman, N I Smorodinsky, M Yaacubovicz, C Schechter, I Bacik, J Gibbs, J R Bennink, J W Yewdell, J E Coligan, H Firat, F Lemonnier, R Ehrlich.   

Abstract

HFE is a nonclassical class I major histocompatibility complex (MHC) molecule that is mutated in the autosomal recessive iron overload disease hereditary hemochromatosis. There is evidence linking HFE with reduced iron uptake by the transferrin receptor (TfR). Using a panel of HFE and TfR monoclonal antibodies to examine human HFE (hHFE)-expressing cell lines, we demonstrate the expression of stable and fully glycosylated TfR-free and TfR-associated hHFE/beta2m complexes. We show that both the stability and assembly of hHFE complexes can be modified by the human cytomegalovirus (HCMV) viral protein US2, known to interfere with the expression of classical class I MHC molecules. HCMV US2, but not US11, targets HFE molecules for degradation by the proteasome. Whether this interference with the regulation of iron metabolism by a viral protein is a means of potentiating viral replication remains to be determined. The reduced expression of classical class I MHC and HFE complexes provides the virus with an efficient tool for altering cellular metabolism and escaping certain immune responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11581431      PMCID: PMC114637          DOI: 10.1128/JVI.75.21.10557-10562.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

Review 1.  Viral subversion of the immune system.

Authors:  D Tortorella; B E Gewurz; M H Furman; D J Schust; H L Ploegh
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  HFE--a novel nonclassical class I molecule that is involved in iron metabolism.

Authors:  R Ehrlich; F A Lemonnier
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

Review 3.  The major histocompatibility complex-encoded HFE in iron homeostasis and immune function.

Authors:  L Salter-Cid; P A Peterson; Y Yang
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

4.  The hemochromatosis protein HFE competes with transferrin for binding to the transferrin receptor.

Authors:  J A Lebrón; A P West; P J Bjorkman
Journal:  J Mol Biol       Date:  1999-11-19       Impact factor: 5.469

5.  Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.

Authors:  N A Georgiou; T van der Bruggen; M Oudshoorn; H S Nottet; J J Marx; B S van Asbeck
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

6.  Iron enhances hepatitis C virus replication in cultured human hepatocytes.

Authors:  S Kakizaki; H Takagi; N Horiguchi; M Toyoda; H Takayama; T Nagamine; M Mori; N Kato
Journal:  Liver       Date:  2000-04

7.  [Effect of iron depletion on long-term response to interferon in patients with chronic hepatitis C with increased plasma iron without accumulation of liver iron].

Authors:  C Cagnoni; F Corsini; D Pancotti; G Carrara
Journal:  Ann Ital Med Int       Date:  2000 Apr-Jun

8.  Cytomegalovirus US2 destroys two components of the MHC class II pathway, preventing recognition by CD4+ T cells.

Authors:  R Tomazin; J Boname; N R Hegde; D M Lewinsohn; Y Altschuler; T R Jones; P Cresswell; J A Nelson; S R Riddell; D C Johnson
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

9.  Antiviral and immunomodulatory effects of desferrioxamine in cytomegalovirus-infected rat liver allografts with rejection.

Authors:  T Martelius; M Scholz; L Krogerus; K Höckerstedt; R Loginov; C Bruggeman; J Cinatl; H W Doerr; I Lautenschlager
Journal:  Transplantation       Date:  1999-12-15       Impact factor: 4.939

10.  Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial.

Authors:  A M Di Bisceglie; H L Bonkovsky; S Chopra; S Flamm; R K Reddy; N Grace; P Killenberg; C Hunt; C Tamburro; A S Tavill; R Ferguson; E Krawitt; B Banner; B R Bacon
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

View more
  22 in total

1.  Back to the fold: T cell recognition of HFE, a MHC class Ib molecule that regulates iron metabolism.

Authors:  Jonathan W Yewdell; Heather D Hickman-Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-29       Impact factor: 11.205

Review 2.  The tug-of-war between dendritic cells and human chronic viruses.

Authors:  Saifur Rahman; Zafar K Khan; Pooja Jain
Journal:  Int Rev Immunol       Date:  2011 Oct-Dec       Impact factor: 5.311

3.  The hemochromatosis protein HFE inhibits iron export from macrophages.

Authors:  Hal Drakesmith; Emma Sweetland; Lisa Schimanski; Jon Edwards; Diana Cowley; Mubeen Ashraf; Judy Bastin; Alain R M Townsend
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-12       Impact factor: 11.205

4.  White spot syndrome virus protein kinase 1 defeats the host cell's iron-withholding defense mechanism by interacting with host ferritin.

Authors:  Shin-Jen Lin; Der-Yen Lee; Hao-Ching Wang; Shih-Ting Kang; Pung-Pung Hwang; Guang-Hsiung Kou; Ming-Fen Huang; Geen-Dong Chang; Chu-Fang Lo
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

5.  Human cytomegalovirus US3 chimeras containing US2 cytosolic residues acquire major histocompatibility class I and II protein degradation properties.

Authors:  Mathieu S Chevalier; David C Johnson
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 6.  Manipulation of iron to determine survival: competition between host and pathogen.

Authors:  Nihay Laham; Rachel Ehrlich
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

7.  Human cytomegalovirus US2 causes similar effects on both major histocompatibility complex class I and II proteins in epithelial and glial cells.

Authors:  Nagendra R Hegde; David C Johnson
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Binding of human cytomegalovirus US2 to major histocompatibility complex class I and II proteins is not sufficient for their degradation.

Authors:  Mathieu S Chevalier; Gwynn M Daniels; David C Johnson
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

9.  Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS.

Authors:  Simon Swingler; Jin Zhou; Catherine Swingler; Ann Dauphin; Thomas Greenough; Paul Jolicoeur; Mario Stevenson
Journal:  Cell Host Microbe       Date:  2008-07-17       Impact factor: 21.023

10.  Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.

Authors:  Nagendra R Hegde; Roman A Tomazin; Todd W Wisner; Claire Dunn; Jessica M Boname; David M Lewinsohn; David C Johnson
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.